Literature DB >> 33504899

Gene co-expression network analysis reveals immune cell infiltration as a favorable prognostic marker in non-uterine leiomyosarcoma.

Mohammad Darzi1, Saeid Gorgin2, Keivan Majidzadeh-A3, Rezvan Esmaeili4.   

Abstract

The present study aimed to improve the understanding of non-uterine leiomyosarcoma (NULMS) prognostic genes through system biology approaches. This cancer is heterogeneous and rare. Moreover, gene interaction networks have not been reported in NULMS yet. The datasets were obtained from the public gene expression databases. Seven co-expression modules were identified from 5000 most connected genes; using weighted gene co-expression network analysis. Using Cox regression, the modules showed favorable (HR = 0.6, 95% CI = 0.4-0.89, P = 0.0125), (HR = 0.65, 95% CI = 0.44-0.98, P = 0.04) and poor (HR = 1.55, 95% CI = 1.06-2.27, P = 0.025) prognosis to the overall survival (OS) (time = 3740 days). The first one was significant in multivariate HR estimates (HR = 0.4, 95% CI = 0.28-0.69, P = 0.0004). Enriched genes through the Database for Annotation, Visualization, and Integrated Discovery (DAVID) revealed significant immune-related pathways; suggesting immune cell infiltration as a favorable prognostic factor. The most significant protective genes were ICAM3, NCR3, KLRB1, and IL18RAP, which were in one of the significant modules. Moreover, genes related to angiogenesis, cell-cell adhesion, protein glycosylation, and protein transport such as PYCR1, SRM, and MDFI negatively affected the OS and were found in the other related module. In conclusion, our analysis suggests that NULMS might be a good candidate for immunotherapy. Moreover, the genes found in this study might be potential candidates for targeted therapy.

Entities:  

Year:  2021        PMID: 33504899      PMCID: PMC7840729          DOI: 10.1038/s41598-021-81952-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  13 in total

1.  Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.

Authors:  Jiefeng Ding; Mei-Ling Kuo; Leila Su; Lijun Xue; Frank Luh; Hang Zhang; Jianghai Wang; Tiffany G Lin; Keqiang Zhang; Peiguo Chu; Shu Zheng; Xiyong Liu; Yun Yen
Journal:  Carcinogenesis       Date:  2017-05-01       Impact factor: 4.944

2.  Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors.

Authors:  David Stahl; Andrew J Gentles; Ralf Thiele; Ines Gütgemann
Journal:  Oncoimmunology       Date:  2019-10-13       Impact factor: 8.110

3.  Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.

Authors:  Emily Z Keung; Melissa Burgess; Ruth Salazar; Edwin R Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; Steven Attia; Richard F Riedel; James Hu; Scott H Okuno; Dennis A Priebat; Sujana Movva; Lara E Davis; Damon R Reed; Alexandre Reuben; Christina L Roland; Denise Reinke; Alexander J Lazar; Wei-Lien Wang; Jennifer A Wargo; Hussein A Tawbi
Journal:  Clin Cancer Res       Date:  2020-01-03       Impact factor: 12.531

4.  Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.

Authors:  Feng Cai; Yingying Miao; Chenyang Liu; Ting Wu; Simei Shen; Xin Su; Yi Shi
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

Review 5.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.

Authors:  Tristan A Barnes; Eitan Amir
Journal:  Br J Cancer       Date:  2017-07-13       Impact factor: 7.640

Review 6.  Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy.

Authors:  Shailaja Raj; Lance D Miller; Pierre L Triozzi
Journal:  Sarcoma       Date:  2018-08-12

7.  Prognostic impact of the tumor immune microenvironment in synovial sarcoma.

Authors:  Naoki Oike; Hiroyuki Kawashima; Akira Ogose; Tetsuo Hotta; Hiroshi Hatano; Takashi Ariizumi; Taro Sasaki; Tetsuro Yamagishi; Hajime Umezu; Naoto Endo
Journal:  Cancer Sci       Date:  2018-09-16       Impact factor: 6.716

8.  A global immune gene expression signature for human cancers.

Authors:  Yuexin Liu
Journal:  Oncotarget       Date:  2019-03-08

9.  SIRT3 regulates cancer cell proliferation through deacetylation of PYCR1 in proline metabolism.

Authors:  Shuaiyi Chen; Xin Yang; Miao Yu; Zhe Wang; Boya Liu; Minghui Liu; Lu Liu; Mengmeng Ren; Hao Qi; Junhua Zou; Ivana Vucenik; Wei-Guo Zhu; Jianyuan Luo
Journal:  Neoplasia       Date:  2019-05-17       Impact factor: 5.715

10.  PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.

Authors:  Juhua Zhuang; Yanan Song; Ying Ye; Saifei He; Xing Ma; Miao Zhang; Jing Ni; Jiening Wang; Wei Xia
Journal:  J Transl Med       Date:  2019-10-16       Impact factor: 5.531

View more
  2 in total

1.  Prognostic and Immune Implications of a Novel Pyroptosis-Related Five-Gene Signature in Breast Cancer.

Authors:  Yuanyuan Zheng; Kainan Wang; Ning Li; Qianran Zhang; Fengxi Chen; Man Li
Journal:  Front Surg       Date:  2022-05-17

Review 2.  Structure, biochemistry, and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase (PYCR), an emerging cancer therapy target.

Authors:  Alexandra N Bogner; Kyle M Stiers; John J Tanner
Journal:  Amino Acids       Date:  2021-05-18       Impact factor: 3.520

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.